

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/050017

International filing date: 16 February 2005 (16.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB  
Number: 0403510.1  
Filing date: 18 February 2004 (18.02.2004)

Date of receipt at the International Bureau: 04 April 2005 (04.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

POT/GB2005/050017



INVESTOR IN PEOPLE


The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*Andrew Gersey*

Dated

14 March 2005



0403510.1

18FEB04 E874074-1 D01049  
P01/7700 A 00-0403510.1

Patents Form 1/77

Patents Act 1877  
(Rule 16)

1/77

**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

THE PATENT OFFICE  
RM  
18 FEB 2004  
RECEIVED BY FAX

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

**1. Your reference**

VERITY,001-P-UK

**2. Patent application number**

(The Patent Office will fill in this part)

0403510.1

18 FEB 2004

**3. Full name, address and postcode of the or of each applicant (underline all surnames)**

Mantra International Ltd.

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

Vigor Industrial Building,  
Block B  
20 Cheung Tat Road  
Tsing Yi  
Hong Kong  
a Hong Kong company

8812158001

**4. Title of the invention**

BIOADHESIVE COMPOSITIONS AND THEIR  
USE IN MEDICAL ELECTRODES

**5. Name of your agent (if you have one)**

COLE, Paul, Gilbert

"Address for service" in the United Kingdom  
to which all correspondence should be sent  
(including the postcode)

Lucas & Co.  
135 Westhall Road  
Warlingham  
Surrey  
CR6 9HJ  
05815709001

Patents ADP number (if you know it)

**6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number**

Country

Priority application number  
(if you know it)Date of filing  
(day / month / year)**7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application**

Number of earlier application

Date of filing  
(day / month / year)**8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer Yes if)**

Yes

- a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or  
c) any named applicant is a corporate body.  
See note (d))

Patents Form 1/77

0094981 18-Feb-04 02:10



## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

## Continuation sheets of this form

Description	32
Claim(s)	3
Abstract	1
Drawing(s)	0

10. If you are also filing any of the following, state how many against each item.

## Priority documents

## Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)	1+1
--	-----

## Request for preliminary examination and search (Patents Form 9/77)

## Request for substantive examination (Patents Form 10/77)

## Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

Paul Cole

18 Feb 04

12. Name and daytime telephone number of person to contact in the United Kingdom

Paul Cole - 01883 626211

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

0094981 18-Feb-04 02:10



## BIOADHESIVE COMPOSITIONS AND THEIR USE IN MEDICAL ELECTRODES

### FIELD OF THE INVENTION

5

This invention relates to bioadhesive compositions which are particularly, but not exclusively, useful for making medical electrodes, and to medical electrodes based on such compositions.

10

### BACKGROUND TO THE INVENTION

Hydrogels are finding considerable use in biomedical applications. Synthetic hydrogels that have bioadhesive properties are finding increased use as conductors, allowing the electrical connection between the skin and the external  
15 medical equipment, the water in the hydrogel providing an ideal medium for dissolution of electrically conductive inorganic salts, thus increasing the electrical conductivity of the hydrogel and its role as a biomedical skin electrode. The external medical equipment could be transcutaneous electric nerve stimulation device, electric muscle stimulation device, electrocardiogram or  
20 monitoring device.

US 4273135 (Larimore, Minnesota Mining and Manufacturing) discloses a "dry" biomedical electrode that does not require cream or gel to enhance conductivity between the skin and the electrode plate. The electrode is of  
25 resistance 100 k $\Omega$  or less at 10 Hz and has on its body-contacting surface a dermally non-irritating conformable cohesive non-ionic synthetic hydrophilic polymer containing at least 15 mole % of a water-soluble monomer that preferably acts as a pressure-sensitive adhesive. The term "cohesive" implies that the film-forming material is more cohesive than it is skin-adherent so that it can  
30 be removed from the skin without leaving an objectionable residue. Electrode materials that were tested include polyacrylic acid plasticised with glycerol, polyvinyl alcohol either alone or plasticised with glycerol, a methyl vinyl



ether/maleic acid copolymer plasticised with glycerol and copolymers of e.g. isooctyl acrylate and acrylic acid. Both tack-free and tacky films were provided.

US-A-4539996 (Engel, Minnesota Mining and Manufacturing) discloses  
5 a further dry biomedical electrode in which the electrode material is  
"solventless" in the sense that there are essentially no materials present in the  
precursor which are not present in the final composition of the electrically  
conductive adhesive. The material is made by UV polymerization and  
incorporates cross-linked polymers which permit higher amounts of polyhydric  
10 alcohol (e.g. 50-70%) without reducing viscosity below acceptable levels. In an  
example, a composition based on acrylic acid (25g), glycerol (50g), tetraethylene  
glycol bis-methacrylate (0.1g), aqueous sodium hydroxide (7 g in 10 ml) and  
photoinitiator was knife-coated onto an aluminium substrate and cured under a  
bank of UV lamps, see also US 4554924 (Engel, Minnesota Mining and  
15 Manufacturing) which discloses materials containing ionizable salts and suitable  
for ECG electrodes.

US-A-3929741 (Lakey, Datascope) discloses hydrophilic acrylamido  
polymers obtained by polymerization of acrylamidoalkyl-sulfonic acid  
20 monomers and are capable of ingurgitating large quantities of liquids,  
particularly water as well as saline and biological fluids, without dissolution of  
the polymer network. The polymers include copolymers with many different  
types of co-monomer including

- 1. Esters of unsaturated polyhydric alcohols (e.g. butenediol).
- 25 • 2. Vinyl cyclic compounds (e.g. styrene, vinyl furane, N-vinyl pyrrolidone).
- 3. Unsaturated acids (e.g. acrylic, methacrylic, propacrylic acid).
- 4. Unsaturated anhydrides (e.g. maleic, citraconic, itaconic).
- 5. Unsaturated nitriles (e.g. acrylonitrile, methacrylonitrile).
- 6. Unsaturated amines (e.g. acrylamide, dimethylaminoethyl methacrylate).
- 30 • 7. Vinyl halides (e.g. vinyl chloride, vinyl iodide, allyl chloride).
- 8. Unsaturated ketones (e.g. methyl vinyl ketone, ethyl vinyl ketone).
- 9. Unsaturated ethers (e.g. methyl vinyl ether, diallyl ether).

- 10. Unsaturated esters (e.g. hydroxyethyl methacrylate, hydroxypropyl acrylate).
- 11. Unsaturated functional silanes.
- 12. Alkyl methacrylates (e.g. methyl methacrylate, ethyl methacrylate).

5

US-A-4391278 (Cahalan, Medtronic) discloses a biomedical electrode in which the skin-contacting material is an adhesive based on a polymer or copolymer of 2-acrylamido-2-methyl-1-propanesulfonic acid or a salt thereof together with water, an alcohol (preferably glycerol or propylene glycol) or a mixture thereof. Polymerization is by addition of a free-radical initiator such as ferrous sulfate and hydrogen peroxide and is also a "solventless" process in the sense defined in US-A-4539996. One example uses 2-acrylamido-2-methyl-1-propanesulfonic acid (25g), acrylic acid (4g) and water (25g) together with small amounts of initiator. The skin-contacting material is said to be inherently electrically conductive so that it does not require electrically conductive additives. It is also said to possess superior adhesive properties, uniform electrical characteristics, adhesive properties that can resist appreciable skin moisture so that the electrodes can be used for several days at a time and homogeneity and creep-resistance so that development of "hot spots" is avoided.

US-A-4768523 (Cahalan *et al.*, Lifecore Biomedical) discloses similar materials made from 2-acrylamido-2-methyl-1-propanesulfonic acid with methylene bis-acrylamide as crosslinking agent and dried to a water content of 2-30 wt % which are aggressively adhesive on initial skin contact and can be used e.g. for attaching pacing leads to epicardial tissue and other moist internal tissue.

25

Cationic hydrogels made from cationic acrylates e.g. acryloyloxyethyl trimethylammonium chloride and 3-acrylamidopropyltrimethylammonium chloride which are non-corrosive to aluminium and can be used for defibrillation and cardiac pacing are disclosed in US-A-5800685 (Perrault, Cardiotronics Systems).

30

US-A-5173302 (Holmblad *et al.*, Medtronic) is concerned *inter alia* with polymerizable formulations curable to produce adhesives on a backing that can be used as a reservoir for topically or transdermally administrable drugs. The adhesives comprise (a) 20%-50% of a monofunctional monomer component at  
5 least 75% of which comprising 2-acrylamido-2-methylpropane sulphonic acid or a salt thereof, the balance being selected from acrylic acid, water soluble acrylic functional monomers and vinyl pyrrolidone, (b) 30%-50% of a glycol component selected from the group consisting of compounds of formula  $\text{HO}-(\text{C}_2\text{H}_4\text{O})_n\text{-H}$ ,  $\text{HO}-(\text{C}_3\text{H}_6\text{O})_m\text{-H}$  and mixtures thereof, where  $n$  is 4-16 and  $m$  is 1-4, (c) between  
10 about 0.02% and about 0.20% of a crosslinking monomer and an amount of a free radical polymerization initiator effective to initiate polymerization of the monofunctional monomer and crosslinking monomer components and (d) water. In an example, a gel material was prepared by combining (where parts are by weight):

- 15 45.25 parts of a 58% solution of NaAMPS in water;  
8 parts of a 1% N,N-methylene-bis-acrylamide solution in water;  
a drug/humectant premix comprising 39.60 parts polyethylene glycol M.W.=300 (PEG 300) and 0.99 parts hydrocortisone;  
silica, 2.48 parts;  
20 acrylic acid, 2.77 parts; and  
photoinitiator (Irgacure.TM. 184), 1 part of a 3% solution in isopropanol).

The degassed mixture was coated through a mesh reinforcement layer of spun bonded polyester onto a polyester sheet material (5 mil Mylar.TM.) and cured with UV radiation of  $1.77 \text{ mW/cm}^2$  from a 365 nm Hg vapor lamp for 1.5  
25 minutes. The cured gel had sufficient adhesion to remain on skin for at least 8 hours.

JP-A-6200224 discloses a new high-adhesion hydrogel composition obtainable by copolymerising by means of UV light 20-60 parts by weight of 2-  
30 acrylamido-2-methyl propane sulphonic acid and/or a salt thereof and 0.03-0.08 parts by weight of a crosslinking monomer at a pH of 5.5 or above in a mixture comprising 20-60 parts by weight of a polyhydric alcohol and 10-50 parts by

weight of an aqueous medium. In an example, 38g of sodium 2-acrylamide-2-methyl propane sulphonate was dissolved in 23.6g of deionized water, which was pH-adjusted to 6.0. To the mixture there were added 38g glycerol, 0.020-0.10 parts by weight of methylene bisacrylamide as a crosslinking monomer and 150 ppm, relative to the amount of the solution of benzoin ethyl ether as a photoinitiator. The ingredients were mixed thoroughly and defoamed in a vacuum, after which the resulting solution was poured into a mould frame, sealed with a polyester film and irradiated with the light from a 15W low-pressure mercury lamp at room temperature for 15 min. to bring about polymerization.

10 The resulting hydrogel composition exhibited good adhesion and good gel, and was low in residual monomers.

US-A-6447798 (Munro *et al.*, First Water Limited) discloses weakly bioadhesive hydrogel compositions suitable for use as wound dressings because they loose adhesion on water uptake. In particular, it discloses a water unstable bioadhesive composition comprising (i) a water activity in the range of 0.4 to 0.9; (ii) an elastic modulus at 1 rad/s in the range of 700 to 15,000 Pa; (iii) an elastic modulus at 100 rad/s in the range of 2000 to 40,000 Pa; (iv) a viscous modulus at 1 rad/s in the range of 400 to 14,000 Pa; and (v) a viscous modulus at 100 rad/s in the range of 1000 to 35,000 Pa, wherein the viscous modulus is less than the elastic modulus in the frequency range of 1 to 100 rad/s.

15  
20

US-A-2002/0015689 and WO 00/46319 (Munro *et al.*, First Water) is concerned with the provision of hydrogel electrodes for adhesion to wet or moist skin and in particular for adhesion to skin to which an artificial layer of grease has been applied e.g. from a moisturising skin cream. For this purpose there is employed a bioadhesive composition formed by polymerising a homogeneous aqueous reaction mixture comprising from about 5% to about 50%, by weight of the reaction mixture, of at least one ionic water soluble monomer, from about 10% to about 50%, by weight of the reaction mixture, of at least one plasticiser (other than water), up to about 50%, by weight of the reaction mixture, of at least one non-ionic water soluble monomer and up to about 40%, by weight of the

25  
30

reaction mixture, of water. The water-soluble monomer is preferably NaAMPS. The plasticiser comprises a polyhydric alcohol (such as glycerol), an ester derived therefrom and/or a polymeric alcohol, for example polyethylene oxide. All the disclosed non-ionic water-soluble monomers are mono- or di-N-alkylacrylamides or analogues thereof. The term "analogue" in this context refers to non-ionic water-soluble monomers containing an alkyl or substituted alkyl group linked to a carbon-carbon double bond via an amido or alkylamido (-CO.NH- or -CO.NR-) function. Examples of such analogues include diacetone acrylamide (N-1,1-dimethyl-3-oxobutyl-acrylamide), N-alkylated acrylamides, N,N-dialkylated acrylamides, N-vinyl pyrrolidone and acryloyl morpholine. The use of monomers of this type gives rise to handling difficulties because at least some are suspected of being carcinogenic, and they have offensive odours, so that they may need to be handled using breathing masks. The compositions are alleged to exhibit "water stability" which is defined to mean the maintenance of adhesion to skin or another substrate from a level of 50% to more than 100% of the value of the "as made" hydrogel adhesive when the water content of the hydrogel has increased by absorption of water (from the environment external to the hydrogel). To provide adhesion to greasy skin the reaction mixture also preferably comprises from about 1% to about 15 wt% of a hydrophobic non-water soluble monomer which may, for example be n-butyl acrylate, n-butyl methacrylate, a hexyl acrylate, iso octyl acrylate, isodecyl acrylate, ethoxyethyl acrylate tetrahydrofurfuryl acrylate, vinyl propionate and vinyl butyrate. One exemplified composition is based on NaAMPS, N,N-dimethylacrylamide, glycerol and polyethylene glycol (400) diacrylate.

25

WO 00/06214 (Munro *et al.*, First Water) discloses hydrogel adhesives for skin electrodes having controlled and predictable adhesive properties and defined in terms of viscoelastic properties and water-activity which should be within the range 0.4 to 0.9 and which should contain both non-freezing and freezing water within the gel. The gels are made from a first monomer which is an acrylamido-alkylsulphonic acid or salt thereof e.g. 2-acrylamido-2-methyl-1-propanesulfonic acid sodium salt (NaAMPS) and a second monomer which is an

30

acrylic acid sulphoalkyl ester or salt thereof e.g. acrylic acid 3-sulphopropyl ester (SPA), potassium salt, preferably in a ratio of 10:1 to 2:3. Comonomers may be present including acrylic acid or a salt or ester thereof. One of the compositions mentioned in an Example comprises 58 parts NaAMPS (50% aqueous solution),  
5 2 parts of SPA, 1.575 parts of acrylic acid and 37 parts of water together with photoinitiator. However, the properties of the resulting cured composition are not described.

### SUMMARY OF THE INVENTION

10

Conductive soft bioadhesive hydrogels in the patent literature have very high water content. One object of the invention is to provide hydrogels in which the bioadhesive and electrical conductivity are not controlled by the water content of the hydrogel, but by the chemical composition of the formulation, in particular the type and level of monomer(s) and plasticiser(s), and in which the  
15 architecture of the polymer network developed and thus the physical properties of the hydrogel depend on the type and level of monomers and plasticiser(s) being used. This allows the development of soft, skin friendly, electrically conductive bioadhesive hydrogels

20

We have found that bioadhesive hydrogels having a desirable combination of properties are obtainable by polymerising an aqueous mixture of two or more water-soluble monomers, aqueous plasticiser and cross-linking agent. In particular, acrylic acid is a water-soluble monomer that is commonly  
25 used in the development of pressure sensitive adhesives, hydrogels and bioadhesive hydrogels. We have found that copolymerisation of acrylic acid with sodium acrylamido tertiary butyl sulfonate (NaAMPS or ABTS-Na) produces hydrogels with useful properties. ABTS-Na is sold as a 50% or 58% solution in water and the available materials provide a useful source of both  
30 monomer and water. The total level of the water in the formulation, and hence water content in the final hydrogel can be controlled by the amount of ABTS-Na

(as 50% or 58% solution) in the formulation as no water is removed during the processing stage.

In one aspect the invention provides a bioadhesive composition  
5 comprising:

(i) 32-52 wt% of a copolymer comprising repeating units derived from one or more monomers selected from olefinically unsaturated sulphonic acids and repeating units derived from one or more olefinically unsaturated carboxylic acids, the ratio by weight of the sulphonic acid units to the carboxylic acid units being from 30:1 to 1:1;  
10

(ii) 25-45 wt% of a plasticizer; and

(iii) 10-35 wt% of water;

the balance being electrolyte and optional ingredients.

15 In a further aspect the invention provides a bioadhesive composition comprising:

(a) 32-52 wt% of a polymer based on repeating units derived from one or more monomers selected from olefinically unsaturated sulphonic acids;

(b) 25-45 wt% of a plasticizer; and

20 (c) 10-35 wt% of water; and

(d) at least one of an alkoxy polyethyleneglycol acrylate or methacrylate and  $\beta$ -carboxyethyl acrylate,

the balance being electrolyte and optional ingredients.

25 In a yet further aspect the invention provides a medical electrode, bandage or the like having an adhesive layer as set out above.

### DESCRIPTION OF PREFERRED EMBODIMENTS

30 By careful selection of the appropriate monomer(s) and their level(s) and the right combination of plasticiser level, hydrogels with a wide spectrum of properties can be developed; from hydrogels being soft, comfortable and easy to

remove after a few hours of skin contact to hydrogels increasing their adhesion as they absorb body moisture, to those that have the ability of adhering to oily skin. Certain embodiments of the above bioadhesive composition provide the only gels that we have so far found that work at all in sweaty conditions.


- 5 Generally, the best current commercially available electrode starts to fall off the skin after only about 30 minutes use in conditions where the ambient temperature is about 30°C and there is significant humidity. In extreme exercise conditions the commercial electrodes hardly adhere at all. However, certain electrodes made using gels of the invention have stayed on and continued to work for hours and
- 10 hours even in very sweaty conditions. Embodiments of the present gel seem to survive and retain their power of adhesion even after more than 100 uses in normal conditions whereas the best current commercial product is basically worn out after about 60 uses even under favourable conditions.

- 15 A significant property of certain embodiments of the present hydrogels is that they increase in adhesion with uptake of water because the gels are "water-starved". The present gels may become softer with water uptake e.g. on repeated re-use while maintaining their adhesive properties and leaving no or substantially no residue, whereas existing gels are prone to dry out with prolonged storage or
- 20 use. The water activity of the gels (defined as the free water in the system) in many embodiments is from less than 0.4 to as low as 0.2, although water activities of up to about 0.65 may be possible in some embodiments. Embodiments of the present gels have relatively low elastic modulus and relatively high viscous elastic modulus due to the use of a low molecular weight
- 25 PEG type plasticiser. Levels of plasticiser content can be used to control the softness of the gel.


- In many compositions of the invention, the copolymer is present in an amount of 35-42 wt% based on the weight of the organic materials and water
- 30 present. A first and predominant type of repeating unit present in the copolymer is derived from one or more monomers selected from olefinically unsaturated sulphonic acids. A preferred class of such acids is of the formula




10



in which  $R^1$  represents hydrogen, methyl or ethyl and  $R^2$  represents a hydrocarbon moiety (e.g. of 3-12 carbon atoms, preferably 3-6 carbon atoms and especially  $-CR^3R^4-CH_2-$  wherein  $R^3$  and  $R^4$  represent hydrogen or straight or branched  $C_1-C_6$  alkyl) and M represents a physiologically acceptable cation. Of this class, the preferred member is acrylamido-2-methyl-1-propanesulfonic acid which may be employed as its lithium, sodium, potassium or ammonium salt. The sodium salt (NaAMPS)



is available from Lubrizol as a 50% aqueous solution (LZ2405) or as a 58% aqueous solution (LZ2405A). The same monomer is available from Toagosei under the name sodium acrylamido tertiary butyl sulfonate (ABTS-Na). A further olefinically unsaturated sulphonic acid of a different class is 3-sulphopropyl acrylate (SPA) which may be used as a salt or analogue. Its sodium salt is of formula:



and has been found to impart softness to gels in which it is contained and to give good water absorption properties. Yet further olefinically unsaturated sulphonic acids include 3-sulphopropyl methacrylate, 2-sulphoethyl acrylate, 2-sulphoethyl methacrylate, vinylsulphonic acid, styrenesulphonic acid, vinyltoluene sulphonic acid and methacrylic sulphonic acid. The above monomer units may occur individually or together with e.g. acrylamido-2-methyl-1-propanesulfonic acid or a salt thereof predominating and minor amounts of 3-sulphopropyl acrylate (SPA) or another of the monomers mentioned above being copolymerised.

However, compositions based on acrylamido-2-methyl-1-propanesulfonic acid or a lithium, sodium, potassium or ammonium salt thereof alone is preferred. For hydrogel compositions containing polymerized AMPS, it may be desirable to control the level of unreacted AMPS, and also the level of impurities such as acrylonitrile, acrylamide, and t-butyl acrylamide, present as monomers in the AMPS starting material. This is so that the level of acrylonitrile, acrylamide, and t-butyl acrylamide are kept within specifically defined target levels in the eventually resulting hydrogel composition see EP-A-1245241.

Suitable weak-acid monomers preferably present as a minor component of the copolymer include those selected from olefinically unsaturated carboxylic acids such as acrylic acid, methacrylic acid, maleic acid, itaconic acid, crotonic acid, ethacrylic acid, citraconic acid, fumaric acid, styrylacrylic acid and the like. The above monomer units may occur individually or in admixture. Acrylic acid and methacrylic acid, polyacrylic acid and mixtures thereof are particularly preferred weak-acid monomers, and alkali metal and ammonium salts e.g. sodium or potassium salts may also be used. For most purposes, the ratio by weight of the sulphonic acid units to the carboxylic acid units is from 23:1 to 16:1, preferably 22:1 to 18:1 and in some particularly preferred compositions about 19:1. The presence of acrylic acid has been found to promote the adhesiveness of the gel. However, we have found that with high levels of acrylic acid and low levels of NaAMPS, the hydrogel produced is stiff, has low bioadhesive properties and does not conform to the skin. With high levels of NaAMPS and low levels of acrylic acid, the hydrogel has good flexibility but loses its adhesion after being on the skin for several times. In contrast to WO 00/06214 where plasticisers (glycerol and PEG 600) are used to control adhesive properties, in the present adhesive materials polyethylene glycol laureate/oleate (ideally molecular weight 400 or 600) and the like are used as plasticizer with glycerol to control the softness of the hydrogel, whereas the adhesion properties are controlled by the amount of total monomer present, in particular the amount of acrylic acid. The addition of polyethylene glycol esters at a level of about 3% of the total plasticizer surprisingly imparts new properties - the hydrogel not

only becomes very soft but is able to stick to oily and sweaty skin, i.e. skin on which natural body oils are present. In this case, the polyethylene glycol esters also start to behave as surfactants.

5           Alternative polymers may be based on just go for NaAMPS/ABTS-Na and/or (a) acryloxloxy-ethyl trimethyl ammonium chloride (or 2-(dimethylamino) ethyl acrylate, methyl chloride quaternary salt), sold under the trade name of ARON DAC (CAS no 44992-01-0) or (b) 3-acrylamidopropyl trimethyl ammonium chloride (ATC) (CAS no 45021-77-0). We could also make  
10       gels using Acryl-(3- sulfopropyl)-ester, potassium salt (SPA), CAS no 31098-20-1, which is also referred to as acrylic acid, (3-sulfopropyl) ester, potassium salt or 3-sulfopropyl acrylate, potassium salt.

          In most compositions the plasticizer is present in an amount of 28-45  
15       wt% based on the weight of the organic materials and water present, preferably 30-35 wt%. The plasticizer should be water-soluble and liquid at ambient  
20       temperatures (25°C). It is preferred to use glycerol which is preferred because it makes the cured composition resistant to dehydration, imparts softness, improves shelf life and does not tend to leach out. It is also inexpensive, biocompatible and  
25       generally regarded as safe. There may also be mentioned other polyols such as propylene glycol, 1,2,4 butane triol, polyethylene oxide and higher-melting polyols that can be dissolved in low melting polyol to give a mixture that is liquid at ambient temperatures. Ethylene glycol is not preferred because it can give rise to adverse dermal reactions. Surprisingly, hydrogels with combined  
30       properties of softness and reusability were prepared when blends of glycerol and polyethylene glycol esters, (such as Polyethylene 400 Glycol Dilaurate, Polyethylene 400 Glycol Monolaurate, Polyethylene 600 Glycol Monolaurate, Polyethylene 400 Glycol Monooleate, Polyethylene 600 Glycol Monooleate, Polyethylene 400 Glycol Dioleate and Polyethylene 600 Glycol Dioleate) were used, or blends thereof. The preferred polyethylene glycol esters would be based on PEG 400 or 600, liquid at room temperature and water soluble. The level of these in the formulation could be from 20% to 0.1%, ideally 10% to 0.5%.

Increasing the level of polyethylene glycol ester above 5% of the total plasticiser in a formulation, decreased the adhesion of the hydrogel dramatically, which is not preferred for a medical electrode adhesive, but would be ideal for applications where bioadhesion of the hydrogel is less important, such as in a wound dressing application. The plasticizer (e.g. glycerol and polyethylene glycol esters) is incorporated into the bioadhesive-forming composition before that composition is polymerised. When glycerol is present as in polymerized hydrogel adhesives made by UV curing, the level of acrolein in the finished composition, may also need to be controlled and kept under well defined target levels, see EP-A-01245241.

The amount of water desired in the composition will vary widely depending upon the other materials present, but in many compositions falls within the range 20-32 wt%, especially about 27-31 wt% water which is relatively low and assists adhesion to individuals who are perspiring e.g. because of hot and high humidity climatic conditions or because of physical exercise. Water that is incorporated into the hydrogel is at the formulation stage and no water is added (or taken out), during the process stage. Frequently the sulphonate monomer(s) will be provided in aqueous solution, and the water in which the monomer is dissolved will provide the entire water content of the cured composition. Hydrogels with close to or less than 20 wt% water content when they are deficient in water ("starved") exhibit the novel and surprising result that the level of adhesion of the hydrogel increases as the body starts to sweat. Conventional hydrogels decrease their adhesive performance as the skin becomes sweaty, and can fall off the skin.

The pH of the gels used according to the invention is advantageously within the mildly acidic range e.g. 2.8-3.6. At this level, microbial activity in the cured product is low, and mould growth is not significant

We have surprisingly found that addition of  $\beta$ -carboxyethyl acrylate  $[\text{CH}_2=\text{CH}-\text{CO}-\text{O}-(\text{CH}_2-\text{CH}_2-\text{CO}-\text{O})_n\text{H}$  where  $n=1$ ] to a copolymer based on

repeating units derived from one or more monomers selected from olefinically unsaturated sulphonic acids and repeating units derived from one or more olefinically unsaturated carboxylic acids can impart softness, flexibility and adhesiveness to the composition. The  $\beta$ -carboxyethyl acrylate may be added in  
5 amounts of 1-10 wt %, typically about 5-8 wt %. For example, the above effects effect have been observed in hydrogels produced on addition of up to 10%  $\beta$ -carboxyethyl acrylate (product of Rhodia and sold under the trade name of Sipomer  $\beta$  CEA) to a mixture of 30% ABTS-Na and 4% acrylic acid and are also noted in other hydrogels exemplified herein.

10

We also found that the introduction of 20% to 0.5%, preferably 2 to 0.5% of an alkoxy polyethyleneglycol acrylate or methacrylate into a copolymer based on repeating units derived from one or more monomers selected from olefinically unsaturated sulphonic acids and repeating units derived from one or more  
15 olefinically unsaturated carboxylic acids can surprisingly improve reusability (number of times that the hydrogel can be adhered to the skin). Such compounds include methoxy polyethylene glycol (350) monoacrylate, methoxy polyethylene glycol (550) monoacrylate, methoxy polyethylene glycol (350) methacrylate and methoxy polyethylene glycol (550) methacrylate, the lower molecular weight  
20 compounds being preferred. Methoxy polyethylene glycol (350) monoacrylate and methacrylate have good water solubility, low Tg (e.g about  $-50^{\circ}\text{C}$ ) and fast surface cure. The low Tg provides a cured material that is flexible at room temperature and even more flexible at body temperature, and therefore contributes significantly to re-usability and softness. Addition of up to 1%  
25 methoxy polyethylene glycol (350) monoacrylate (product of Sartomer and sold under the trade name of Sartomer CD-551) has proved effective in increasing hydrogel reusability. We believe this is also due to the incorporation of long side chains into the 3 dimensional structured polymer network hydrogel produced by co-polymerisation of ABTS-Na, acrylic acid and/or Sipomer  $\beta$  CEA with the  
30 methoxy polyethylene glycol (350) monoacrylate (Sartomer CD 551).

The introduction of a cationic olefinic comonomer e.g a small amount of acryloyl oxyethyl trimethyl ammonium chloride (product of Toagosei Chemicals and sold under the trade name of ARON DAC) made a small contribution to the electrical performance of the hydrogel produced and also provides 'tough' body to the hydrogel.

The addition of small amounts of chloride salt, in particular potassium chloride at 1-10 wt %, preferably 3-5 wt% also improves the electrical performance of hydrogels when they are being used for biomedical electrode application. It can conveniently be dissolved in the aqueous solution of the sulphonic monomer prior to polymerisation.

The development of the three-dimensional cross-linked polymer network is achieved from UV assisted photopolymerisation from a mixture of water-soluble monomers. The preferred means of catalysing the reaction is through the use of UV photo-initiators. A number of suitable UV photoinitiators have been employed in the polymerisation of monomers for adhesive hydrogels, such as 1-hydroxycyclohexyl phenyl ketone and 2-hydroxy-2-methyl-1-phenyl-1-propanone (both products of Ciba Speciality Chemicals and marketed under the trade names of Daracur 1173 and Irgacure 184, respectively). We have found that the use of both photoinitiators imparts enhanced bioadhesive properties to the hydrogel produced. We find that whereas Irgacure 184 provides hydrogel with good surface adhesion, Daracur 1173 has the ability to provide good bulk polymerisation. The use of Irgacure 754 and Irgacure 819 DW (both product of Ciba Speciality Chemicals and recently available in bulk) for producing bioadhesive hydrogels is believed to be novel.

Conventional crosslinking agents may be used to provide the necessary mechanical integrity and control the adhesive properties of the formulation. Typical cross-linkers include polyethylene glycol (PEG 600) diacrylate and polyethylene glycol (PEG 400) diacrylate (both products of UCB Chemicals and

marketed under the trade name of Ebecryl 11 and IRR 280. The level of crosslinker could range from 0.3% to 0.01%, ideally from 0.1% to 0.04%.

Irgacure 184 is not normally used as a photoinitiator when water-soluble monomers are used because of its insolubility in water. However, the polyethylene glycol diacrylate cross-linkers have the ability of dissolving Irgacure 184, the solution being stable for use in polymerising water-soluble monomers. Because Daracur 1173 has good water solubility it is preferred to ensure that it is able to provide total cure of monomers in the production of thick hydrogels (up to 2mm), at a fast rate, allowing quick cross-linking by the water-soluble cross-linkers.

The addition of a small amount of hydrophobic pressure sensitive acrylic copolymer emulsion, such as Flexbond MV70H and Airflex 920, (both products of Air Products), was found to increase the surface tack of the hydrogel. Copolymers having very low glass transition temperatures ( $T_g$ ) were found to provide better adhesion.

Unexpectedly, it was found that it was unnecessary to remove the high levels of inhibitors, such as MHEQ, used to stabilise the monomers from premature catalysis for preparation of sheet hydrogels, at reasonable rates of cure, using photopolymerisation technique.

The low level of water content of the sheet hydrogels produced was, surprisingly, acceptable in using these type of hydrogels to deliver essential oils (such as chamomile and basil) and natural moisturisers (such as Lu Hui (aloe vera), jasmine, lavender, palmarosa, and rose hip oil) to the surface of the skin. The presence of glycerol and polyethylene glycol esters in the sheet hydrogels enhances the solubility of essential oils and natural skin moisturisers.

30

The invention will now be further described in the following examples.

**Chemicals used****Monomers:**

5 Acrylamido-2-Methyl-1-propane sulfonic acid sodium salt (50% aqueous solution)

i. From Lubrizol as L2405 (NaAMPS)

ii. From Toagosei as ATBS-Na

The 58% aqueous solution of NaAMPS/ATBS-Na, either from Lubrizol or Toagosei can also be used for these formulations.

10

Acryl-(3- sulfopropyl) - ester, potassium salt (SPA)

15

Methoxy polyethylene glycol (350) monoacrylate or 550 monoacrylate (sold as Sartomer CD-551 and Sartomer CD553, respectively by Sartomer).

Methoxy polyethylene glycol 350 methacrylate or 550 methacrylate (sold as Sartomer CD550 and Sartomer CD552, respectively by Sartomer).

20

$\beta$ -Carboxyethyl Acrylate, sold as Sipomer  $\beta$  CEA by Rhodia.

Acrylic acid

25

(3-acrylamidopropyl)trimethylammonium chloride (ATC) (as 70% aqueous solution).

Acryloyloxy-ethyl trimethyl ammonium chloride (DAC) (as 80% aqueous solution)

**Crosslinkers:**

30

Ebecryl 11 (Polyethylene glycol (600) diacrylate)

IRR 280 (Polyethylene glycol (400) diacrylate)



**Photoinitiators:**

Irgacure 184

Daracur 1173

5

**Plasticizers:**

Glycerol

Polyethylene 400 Dilaurate (PEG 400 DL)

Polyethylene 400 Monolaurate (PEG 400 ML)

10 Polyethylene 600 Monolaurate (PEG 600 ML)

Polyethylene 400 Monooleate (PEG 400 MO)

Polyethylene 600 Monooleate (PEG 600 MO)

Polyethylene 400 Dioleate (PEG 400 DO)

Polyethylene 600 Dioleate (PEG 600 DO)

15

**Tackifiers:**

Rosin ester (food grade)

Flexbond MV70H (Air Products)

Airflex 920 (Air Products)

20 BJ707 (Beijing Organic Chemical Plant)

BJ705 (Beijing Organic Chemical Plant)

**Essential oils and natural moisturisers:**

25 Basil, chamomile, jasmine, lavender, palmarosa and rose hip essential oils are obtained from Kobashi.

Aloe Vera (Lu Hui)

30 In the form of 1:1, 10:1 gel or whole leaf concentrate or as 100:1 or 200:1 whole leaf freeze dried powder from Yunnan Yuanjiang Evergreen Biological Industry (Group) Co Ltd. Aloe vera freeze dried powder is preferred if a water limited

formulation is required. In this case, the aloe vera is reconstituted using the water contained by the ATBS-Na or the NaAMPS monomer in the formulation.

5

### Method of preparing formulations:

#### Stage 1

Photoinitiator is dissolved in the cross linker or mixed with the crosslinker if a liquid photoinitiator is used. For example in 30 parts of polyethylene glycol diacrylate (PEG 600) (product of UCB Chemicals and marketed under the trade name of Ebacyl 11), 6 parts of 1-hydroxycyclohexyl phenyl ketone (product of Ciba, trade name Irgacure 184) are dissolved to give solution A or PI/XL mix.

15

#### Stage 2:

KCl is mixed in ABTS-Na (or the NaAMPS), until dissolved, after which glycerol is added to the mixture, followed by polyethylene glycol 400 dioleate (if used). The remaining monomers (Sartomer CD550, DAC, CEA and acrylic acid in this order) are added and the mixture is stirred after each addition.

20

#### Stage 3:

The PI/XL mixture (appropriate level) is added to the mixture prepared in stage 2.

25

#### Stage 4:

Liquid mixture is poured onto siliconised PET sheet and placed under a medium pressure mercury UV lamp for 10 to 24 seconds.

30

5

**Example 1****Effect of methoxy polyethylene glycol 350 monomethacrylate (CD550)**

The following resins were prepared using the technique described above.

10

Reference	1-1	1-2	1-3	1-4
Acrylic Acid	20	3	20	20
NaAMPS(50%)	0	64	0	20
SPA	20	0	17.5	7.5
CD550	0	1	2.5	2.5
Glycerol	30	30	30	30
Water	30	0	30	20
KCl	3	3	3	3
Irgacure184/Ebecryl11(6/20)	0.12	0.12	0.12	0.12
Cure time(s)	12	12	12	12
Monomer%	40	36	40	40
Water%	30	32	30	30

The addition of SPA resulted in soft hydrogels. The increase of CD 550 content was found to increase the re-usability of the resulting gels.

15

5

**Example 2**

**Effect of methoxy polyethylene glycol 350 monoacrylate (CD551) and  
Sipomer  $\beta$  (CEA)**

10

The following resins were prepared using the technique described above,  
formed into electrodes and evaluated.

Reference	2-1	2-2	2-3	2-4
Acrylic Acid	3	3	3	3
NaAMPS(50%)	57	57	57	57
CD551	1	2	3	4
CEA	6	5	4	3
Glycerol	33	33	33	33
KCl	5	5	5	5
Irgacure 184/Ebecryl 11 (6/30)	0.08	0.08	0.08	0.08
Cure time(s)	12	12	12	12
Monomer%	38.5	38.5	38.5	38.5
Water%	28.5	28.5	28.5	28.5

15

The combined effect of CEA and CD551 was to increase the re-usability  
of the hydrogel produced.

20

**Example 3**

5

**Effect of acryloyloxy-ethyl trimethyl ammonium chloride (DAC) and Sipomer  $\beta$  (CEA)**

The following resins were prepared using the technique described above.

10

Reference	3-1	3-2	3-3	3-4
Acrylic Acid	3	3	3	3
NaAMPS(50%)	57	57	57	57
DAC	1	2	3	4
CEA	6	5	4	3
Glycerol	33	33	33	33
KCl	5	5	5	5
Irgacure 184/Ebecryl 11 (6/30)	0.08	0.08	0.08	0.08
Cure time(s)	12	12	12	12
Monomer%	38.5	38.5	38.5	38.5
Water%	28.5	28.5	28.5	28.5

Increasing content of acryloyloxy-ethyl trimethyl ammonium chloride (DAC) lead to an increase in the toughness of the electrode gels, but decreased their capacity to absorb water, so that their ability to adhere to the skin of a subject who was perspiring was reduced.

15

**Example 4**

5

**Effect of of methoxy polyethylene glycol 350 monoacrylate (CD551), acryloyloxy-ethyl trimethyl ammonium chloride (DAC) and and Sipomer  $\beta$  (CEA)**

10

The following resins were prepared using the technique described above.

Reference	4-1	4-2	4-3	4-4
Acrylic Acid	3	3	3	3
NaAMPS(50%)	57	57	57	57
CD551	1	1	1	1.5
DAC	2	3	5	0.5
CEA	4	3	1	5
Glycerol	33	33	33	33
KCl	5	5	5	5
Irgacure 184/Ebecryl 11 (6/30)	0.08	0.08	0.08	0.08
Cure time(s)	12	12	12	12
Monomer%	38.5	38.5	38.5	38.5
Water%	28.5	28.5	28.5	28.5

15

The combined effects of DAC and CEA was to increase the toughness of the resulting gels, but their skin adhesion properties were only moderately good, with some improvement in the reusability of the resulting gel.

**Example 5**

5

**Effect of high monomer content**

- 10 The following resins were prepared using the technique described above.  
ATC refers to acrylamido trimethyl ammonium chloride.

Sample	5-1	5-2	5-3
Acrylic Acid	3	3	3
NaAMPS(50%)	59	54	49
CD551	1	1	1
ATC	5	10	15
Glycerol	30	30	30
PEG400MO	2	2	2
KCl	0	0	0
Irgacure 184/Ebecryl 11 (6/20)	0.10	0.10	0.10
Cure time(s)	12	12	12
Monomer%	37.25	38.5	39.75
Water%	30.75	29.5	28.25

15

The above gels were of relatively high water content and exhibited relatively poor adhesion properties because of the high content of ATC monomer.

20

**Example 6****Effect of high monomer content**

- 5           The following resins were prepared using the technique described above.  
ATC refers to acrylamido trimethyl ammonium chloride

Reference	6-1	6-2	6-3	6-4	6-5
Acrylic acid	5	3	5	3	6
NaAMPS(50%)	49	62	49 (58%)	53 (58%)	49 (58%)
CD551	1	0	1	0	1
SPA	8	0	8	6	8
ATC	5	0	5	1	0
CEA	0	5	0	5	7
Glycerol	30	30	30	30	30
PEG400MO	2	0	2	2	2
KCl	0	0	0	0	0
Irgacure 184/Ebecryl 11 (6/20)	0.10	0.10	0.10	0.10	0.10
Cure time(s)	12	12	12	12	12
Monomer%	42.25	39	46.17	45.49	51
Water%	25.75	31	21.83	22.51	20

10

- Where the level of ATC was more than 1%, the resulting gel had low skin adhesion, but good electrical properties. When the monomer level was more than 45% (and contained low levels of ATC), the resulting gel had good adhesion to skin. When gel with such a formulation was placed on sweaty skin, the adhesion of the gel increased. Gels made from formulations 6-4 and 6-5 were found to increase in adhesion on skin as it became sweatier. It is possible that the small level of PEG400 MO is sufficient it to behave as a surfactant in these formulations.

20



**Example 7****Effect of CEA**

The following resins were prepared using the technique described above.

Reference	7-1	7-2	7-3	7-4	7-5	7-6
Acrylic Acid	3	3	3	3	3	3
CD551	0	0	0	0	0	0.5
ATBS-Na (50%)	62	62	60	60	68	60
SPA	0	0	2	0	0	0
CEA	5	5	5	8	0	8
Glycerol	30	28	29	28	29	28
Water	0	0	0	0	0	0
KCl	3	3	3	3	3	3
PEG400DL	0	2	1	1	0	0.5
Irgacure 184/Ebecryl 11 (6/30)	0	0	0	0.12	0.12	0.12
Darocur 1173/Ebecryl 11 (6/20)	0.10	0.12	0.10	0	0	0
Darocur 1173	0	0	0	0	0	0.01
Cure time(s)	12	12	12	12	12	13
Monomer%	39	39	40	41	37	41.5
Water%	31	31	30	30	34	30

- 15      The above gel exhibited reasonable skin adhesion properties; sample 7-6 had the highest adhesion due to having a low water content but a high monomer content.

27

**Example 8****Effect of ATC**

The following resins were prepared using the technique described above.

10

Reference	8-1	8-2	8-3
Acrylic Acid	3	3	3
NaAMPS(50%)	59	54	49
ATC	5	10	15
CD551	1	1	1
Glycerol	30	30	30
PEG400MO	2	2	2
KCl	3	3	3
Irgacure 184/Ebecryl 11 (6/20)	0.10	0.10	0.10
Cure time(s)	12	12	12
Monomer%	37.25	38.5	39.75
Water%	30.75	29.5	28.25

The addition of ATC increased the electrical performance of the resulting  
15 gel, but their skin adhesion properties were very poor.

**Example 9****5 Effect of photoinitiator**

The following resins were prepared using the technique described above.

Reference	9-1	9-2
Acrylic Acid	3	3
NaAMPS(50%)	62	62
CEA	5	5
Glycerol	30	30
KCl	3	3
Irgacure 184/Ebecryl 11 (6/20)	0.10	0
Darocur 1173/Ebecryl 11 (6/20)	0	0.10
Cure time(s)	12	12
Monomer%	39	39
Water%	31	31

10

The resulting gels had reasonable adhesion properties.

**Example 10****Effect of cross-linker level**

- 5 The following resins were prepared using the technique described above.

Reference	10-1	10-2
Acrylic Acid	3	3
ATBS-Na(50%)	60	60
SPA	2	2
CEA	5	5
Glycerol	29	29
KCl	3	3
PEG400DL	1	1
Irgacure 184/Ebecryl 11 (6/20)	0.15	0.20
Darocur 1173	0.10	0.10
Cure time(s)	12	12
Monomer%	40	40
Water%	30	30

Increase in the cross-linker level resulted in the gel being slightly harder.

10

**Example 11****Effect of SPA and CD 550**

The following resins were prepared using the technique described above.

15

Reference	11-1	11-2	11-3	11-4	11-5	11-6
Acrylic Acid	3	3	3	3	3	0
NaAMPS(50%)	64	60	62	64	62	62
CD550	1	0	1	1	1	3
SPA	0	6	2	0	2	0
CEA	0	0	0	0	0	5
Glycerol	30	30	30	30	30	30
PEG400DL	2	1	2	2	0	0
PEG400ML	0	0	0	0	2	0
KCl	3	3	3	3	3	3
Ir184/Eb11(6/20)	0.1	0.1	0.1	0.12	0.12	0.10

30

Cure time(s)	12	12	12	12	12	12
Monomer%	36	39	37	36	12	39
Water%	32	30	31	32	37	31

The combination of SPA and CD550 resulted in gels that were soft and reusable.

5

**Example 12****Effect of tackifer**

10

The following resins were prepared using the technique described above.

Reference	12-1	12-2	12-3	12-4
Acrylic Acid	3	3	4	4
ATBS-Na(50%)	46	46	46	44
CD551	0	0	0.5	0.5
DAC	0	0	1	3
CEA	8	8	8	8
Glycerol	28	28	21.5	21.5
KCl	3	3	3	3
BJ707	0	0	15	15
Flexbond MV70H	15	0	0	0
Airflex 920	0	15	0	0
Irgacure 184/Ebecryl 11 (6/30)	0.12	0.12	0.12	0.12
Monomer%	41.5	41.5	43.75	44.25
Water%	28	28	30.75	30.25

15

The addition of Flexbond MVOH and Airflex 920 had the effect of increasing the skin adhesion of the gel. The tackifer BJ707 had little effect in increasing the skin adhesion of the gel.

20

31

## Example 13

## Addition of Aloe Vera

The following resin was prepared using the technique described above:

5

Reference	13-1
ATBS (50%)	62
CD550	1.9
Aloe Vera (freeze dried whole leaf powder 200:1)	0.1
Glycerol	30
PEG400DL	3
Irgacure 184/Ebecryl 11(6/20)	0.12
Cure time(s)	12
Monomer%	34.9
Water%	30

The gel had a cool, soft feeling and low adhesion to the skin.

## Example 14

10

## Effect of glycerol and polyethylene glycol

The following formulations were made and were evaluated for use as adhesives in medical electrodes with the results indicated below

Reference	14-01	14-02	14-03	14-04	14-05	14-06	14-07	14-08	14-09
Acrylic Acid	3	3	3	3	3	3	3	3	3
NaAMPS(50%)	64	60	60	57	56	57	66	62	57
CD550	1	5	1	5	1	10	0	0	0
Glycerol	30	30	30	30	30	30	30	30	30
PEG400DL	2	2	6	5	10	1	1	5	10
Irgacure 184/Ebecryl 11(6/20)	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Cure time(s)	12	12	12	12	12	12	12	12	12
Monomer%	36	38	34	36.5	32	41.5	36	34	31.5
Water%	32	30	30	28.5	28	28.5	33	31	28.5
Glycerol+PEG	32	32	36	35	40	31	31	35	40
Glycerol/PEG	30/2	30/2	30/6	30/5	30/10	30/1	30/1	30/5	30/10

32

Increasing the level of PEG400DL resulted in the gel becoming softer,  
with increased adhesion on oily skin.

---

## CLAIMS

1. A bioadhesive composition comprising:
  - (i) 32-52 wt% of a copolymer comprising repeating units derived  
5 from one or more monomers selected from olefinically unsaturated sulphonic acids and repeating units derived from one or more olefinically unsaturated carboxylic acids, the ratio by weight of the sulphonic acid units to the carboxylic acid units being from 30:1 to 1:1;
  - (b) 25-45 wt% of a plasticizer; and
  - 10 (c) 10-35 wt% of water;the balance being electrolyte and optional ingredients.
2. The composition of claim 1, comprising as sulphonic acid units 2-acrylamido-2-methyl-propanesulphonic acid or a salt thereof.
- 15 3. The composition of claim 1, comprising as sulphonic acid units 2-acrylamido-2-methyl-propanesulphonic acid sodium salt (NaAMPS).
4. The composition of any preceding claim comprising as sulphonic acid  
20 units 3-sulphopropyl acrylate (SPA) or a salt or analogue thereof.
5. The composition of any preceding claim, comprising as carboxylic acid units acrylic acid, methacrylic acid or a mixture thereof.
- 25 6. The composition of any preceding claim, comprising 35-42 wt% of the copolymer.
7. The composition of any preceding claim, wherein the ratio by weight of sulphonic acid units to carboxylic acid units is from 23:1 to 16:1.
- 30 8. The composition of any of claims 1-6, wherein the ratio by weight of sulphonic acid units to carboxylic acid units is from 22:1 to 18:1.



9. The composition of any of claims 1-6, wherein the ratio by weight of sulphonic acid units to carboxylic acid units is about 19:1.
10. The composition of any preceding claim, comprising 28-45 wt% plasticizer.
11. The composition of any preceding claim, comprising 30-33 wt% plasticizer.
12. The composition of any preceding claim, wherein the plasticizer is a water-soluble polyhydric alcohol that is liquid at ambient temperatures.
13. The composition of any preceding claim, wherein the plasticizer is glycerol or a mixture of glycerol and one or more other polyols.
14. The composition of any preceding claim, comprising 25-32 wt% water.
15. The composition of any of claims 1-13, comprising 27-31 wt% water.
16. The composition of any preceding claim, further comprising an alkoxy polyethyleneglycol acrylate or methacrylate.
17. The composition of claim 16, further comprising 1-10 wt%  $\beta$ -carboxyethyl acrylate.
18. The composition of claim 16, further comprising 5-8 wt%  $\beta$ -carboxyethyl acrylate.
19. The composition of any preceding claim, further comprising an alkoxy polyethyleneglycol acrylate or methacrylate.

20. The composition of claim 19, wherein the alkoxy polyethyleneglycol acrylate or methacrylate is methoxy polyethylene glycol monoacrylate.
22. The composition of claim 19, wherein the alkoxy polyethyleneglycol acrylate or methacrylate is methoxy polyethylene glycol methacrylate.
23. The composition of any of claims 19-22, wherein the alkoxy polyethylene glycol acrylate or methacrylate is present in an amount of 1-3 wt%.
24. A bioadhesive composition comprising:
- (a) 32-52 wt% of a polymer based on repeating units derived from one or more monomers selected from olefinically unsaturated sulphonic acids;
  - (b) 25-45 wt% of a plasticizer; and
  - (c) 10-35 wt% of water;
  - (d) at least one of an alkoxy polyethyleneglycol acrylate or methacrylate and  $\beta$ -carboxyethyl acrylate, the balance being electrolyte and optional ingredients.
25. A medical electrode, bandage or the like having a layer of a bioadhesive composition as claimed in any preceding claim.
26. A medical electrode that could be used on soft, sensitive skin of the body for monitoring or stimulation applications.
27. A medical electrode, bandage or the like having a layer of bioadhesive composition that also has the ability to deliver essential oils and natural moisturisers to the skin.

ABSTRACT

BIOADHESIVE COMPOSITIONS AND THEIR  
USE IN MEDICAL ELECTRODES

5

This invention relates to bioadhesive compositions which are particularly, but not exclusively, useful for making medical electrodes, and to medical electrodes based on such compositions. A first bioadhesive composition comprises:

10 (i) 32-52 wt% of a copolymer comprising repeating units derived from one or more monomers selected from olefinically unsaturated sulphonic acids and repeating units derived from one or more olefinically unsaturated carboxylic acids, the ratio by weight of the sulphonic acid units to the carboxylic acid units being from 30:1 to 1:1;

15 (b) 25-45 wt% of a plasticizer; and

(c) 10-35 wt% of water;

the balance being electrolyte and optional ingredients.

A second bioadhesive composition comprising:

20 (a) 32-52 wt% of a polymer based on repeating units derived from one or more monomers selected from olefinically unsaturated sulphonic acids;

(b) 25-45 wt% of a plasticizer; and

(c) 10-35 wt% of water;

(d) at least one of an alkoxy polyethylenglycol acrylate or methacrylate and  $\beta$ -carboxyethyl acrylate,

25 the balance being electrolyte and optional ingredients.



